Figure S7. Expression analysis for the high affinity neoepitopes (FPKM ≥ 2). (A) The number of the expressed neoepitopes (normalized by total number of samples in each breast cancer subtype) is shown for each FPKM range. 51% (8927/17518) of predicted neoepitopes are expressed with an FPKM threshold of ≥ 2 . (B) Number of neoepitopes (normalized by the number of samples in each breast cancer subtype) with the highest expressed neoepitope for each patient as shown. 93% (762/815) of patients have at least one potential binding epitope. <1 includes neoepitopes with expression less than 1.0 FPKM (not including 1.0 FPKM), 1-2 includes neoepitopes with expression equal to or greater than one and less than 2 FPKM, and so on, for all categories.

